NLS Pharmaceutics AG Appoints CBIZ as New Auditor Amid Internal Control Weaknesses

Reuters
09/23
NLS Pharmaceutics AG Appoints CBIZ as New Auditor Amid Internal Control Weaknesses

NLS Pharmaceutics AG has announced a change in its independent registered public accounting firm following the acquisition of Marcum LLP's attestation business by CBIZ CPAs P.C. As of September 17, 2025, Marcum LLP resigned as the company's auditor, and CBIZ was engaged to take over the role for the fiscal year ending December 31, 2025. The transition was approved by the Audit Committee of NLS Pharmaceutics' Board of Directors. Notably, Marcum's report on the company's financial statements for the fiscal year ended December 31, 2024, did not contain any adverse opinions or disclaimers but did highlight substantial doubt about the company's ability to continue as a going concern. Additionally, the company disclosed material weaknesses in its internal control over financial reporting, specifically related to a lack of trained accounting professionals and insufficient segregation of duties.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-089523), on September 19, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10